Agile process and plant engineering for the pharmaceutical industry

The pharmaceutical industry is facing numerous challenges, including increasing demand for drugs and therapies, the rise of innovative products like cell and gene therapies, and changing regulations. To overcome these obstacles and maintain quality, pharmaceutical companies must be agile and capable of ramping up production efficiently. This ebook outlines how adopting an agile process and plant engineering approach can help companies accelerate operational readiness and make their manufacturing sites more adaptable to anticipate production needs.

Addressing pharmaceutical industry challenges

As pharmaceutical companies grapple with rising demand for medications, driven by factors like the aging population, this is putting significant pressure on companies to deliver products faster. Changing regulations and supply chain complications further compound the complexity these manufacturers face in increasing speed, efficiency, agility and sustainability while maintaining quality. Agile process and plant engineering provides a solution to these challenges by enabling pharmaceutical companies to streamline interdisciplinary collaboration, optimize production processes and enhance flexibility in their manufacturing operations.

Adopting an agile process and plant engineering approach

Adopting an agile process and plant engineering approach can give pharmaceutical companies the tools to anticipate and adapt to uncertainties. This includes streamlining interdisciplinary collaboration, enabling efficient and integrated engineering, validating and optimizing processes using digital twins, and delivering greater versatility and faster start-up times through standardization and modular automation. By implementing these solutions, pharmaceutical companies can increase scalability for varying production demands, optimize facility layouts, and accelerate their time-to-market.

Download the ebook and learn how to adapt your manufacturing processes to handle diverse drug product portfolios and fluctuating demand.